A Multidisciplinary Hyper-Modeling Scheme in Personalized In Silico Oncology: Coupling Cell Kinetics with Metabolism, Signaling Networks, and Biomechanics as Plug-In Component Models of a Cancer Digital Twin.

The massive amount of human biological, imaging, and clinical data produced by multiple and diverse sources necessitates integrative modeling approaches able to summarize all this information into answers to specific clinical questions. In this paper, we present a hypermodeling scheme able to combine models of diverse cancer aspects regardless of their underlying method or scale. Describing tissue-scale cancer cell proliferation, biomechanical tumor growth, nutrient transport, genomic-scale aberrant cancer cell metabolism, and cell-signaling pathways that regulate the cellular response to therapy, the hypermodel integrates mutation, miRNA expression, imaging, and clinical data. The constituting hypomodels, as well as their orchestration and links, are described. Two specific cancer types, Wilms tumor (nephroblastoma) and non-small cell lung cancer, are addressed as proof-of-concept study cases. Personalized simulations of the actual anatomy of a patient have been conducted. The hypermodel has also been applied to predict tumor control after radiotherapy and the relationship between tumor proliferative activity and response to neoadjuvant chemotherapy. Our innovative hypermodel holds promise as a digital twin-based clinical decision support system and as the core of future in silico trial platforms, although additional retrospective adaptation and validation are necessary

A multidisciplinary hyper-modeling scheme in personalized in silico oncology : coupling cell kinetics with metabolism, signaling networks, and biomechanics as plug-in component models of a cancer digital twin

The massive amount of human biological, imaging, and clinical data produced by multiple and diverse sources necessitates integrative modeling approaches able to summarize all this information into answers to specific clinical questions. In this paper, we present a hypermodeling scheme able to combine models of diverse cancer aspects regardless of their underlying method or scale. Describing tissue-scale cancer cell proliferation, biomechanical tumor growth, nutrient transport, genomic-scale aberrant cancer cell metabolism, and cell-signaling pathways that regulate the cellular response to therapy, the hypermodel integrates mutation, miRNA expression, imaging, and clinical data. The constituting hypomodels, as well as their orchestration and links, are described. Two specific cancer types, Wilms tumor (nephroblastoma) and non-small cell lung cancer, are addressed as proof-of-concept study cases. Personalized simulations of the actual anatomy of a patient have been conducted. The hypermodel has also been applied to predict tumor control after radiotherapy and the relationship between tumor proliferative activity and response to neoadjuvant chemotherapy. Our innovative hypermodel holds promise as a digital twin-based clinical decision support system and as the core of future in silico trial platforms, although additional retrospective adaptation and validation are necessary

Preliminary Evaluation of a Web-Oriented Assessment Tool for Emotion Recognition

International audiencePerceiving and identifying emotions on facial expressions is one of the basic abilities that compose emotional intelligence, and is crucial for normal social functions. It is well documented that facial expression conveys information about felt emotion, and that expressive behavior can activate or regulate the emotion required by a given situation. Instruments measuring emotion perception based on facial expression have been found in literature either as stand-alone scales or as part of other tests. The proposed tool expands existing instruments to combine online availability while affording assessment of emotion recognition on a continuum of intensity. It was founded on Ekman's Facial Action Units, with two Virtual Characters (male and female) portraying five basic emotions Anger, Disgust, Fear, Joy, Sadness, plus Neutral expression. The user can navigate on the custom-made pentagon and choose the emotion and intensity level (1-5) through a single click. The preliminary evaluation of the tool on thirty normal subjects provided threshold data that can later be used as benchmarks to assess emotion perception sensitivity in psychiatric disorders such as depression and schizophrenia characterized by emotional dysfunction

The mathematical path to develop a heterogeneous, anisotropic and 3-dimensional glioma model using finite differences

Summarization: Several mathematical models have been developed to express glioma growth behavior. The most successful models have used the diffusion-reaction equation, with the most recent ones taking into account spatial heterogeneity and anisotropy. However, to the best of our knowledge, there hasn't been any work studying in detail the mathematical solution and implementation of the 3D diffusion model, addressing all related heterogeneity and anisotropy issues. This paper presents a complete mathematical framework on how to derive the solution of the equation using different numerical schemes of finite differences. Moreover, the derived mathematics can be customized to incorporate various cell proliferation schemes. Lastly, a comparative study of the numerical scheme helps us select the best of them and then apply it to real clinical data.Presented on

A Multidisciplinary Hyper-Modeling Scheme in Personalized In Silico Oncology: Coupling Cell Kinetics with Metabolism, Signaling Networks, and Biomechanics as Plug-In Component Models of a Cancer Digital Twin

Peer reviewed: TruePublication status: PublishedThe massive amount of human biological, imaging, and clinical data produced by multiple and diverse sources necessitates integrative modeling approaches able to summarize all this information into answers to specific clinical questions. In this paper, we present a hypermodeling scheme able to combine models of diverse cancer aspects regardless of their underlying method or scale. Describing tissue-scale cancer cell proliferation, biomechanical tumor growth, nutrient transport, genomic-scale aberrant cancer cell metabolism, and cell-signaling pathways that regulate the cellular response to therapy, the hypermodel integrates mutation, miRNA expression, imaging, and clinical data. The constituting hypomodels, as well as their orchestration and links, are described. Two specific cancer types, Wilms tumor (nephroblastoma) and non-small cell lung cancer, are addressed as proof-of-concept study cases. Personalized simulations of the actual anatomy of a patient have been conducted. The hypermodel has also been applied to predict tumor control after radiotherapy and the relationship between tumor proliferative activity and response to neoadjuvant chemotherapy. Our innovative hypermodel holds promise as a digital twin-based clinical decision support system and as the core of future in silico trial platforms, although additional retrospective adaptation and validation are necessary.</jats:p